
## Rebecca Hoh

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/53856/publications.pdf Version: 2024-02-01



REBECCA HOH

#	Article	IF	CITATIONS
1	Cellular Activation, Differentiation, and Proliferation Influence the Dynamics of Genetically Intact Proviruses Over Time. Journal of Infectious Diseases, 2022, 225, 1168-1178.	1.9	9
2	Deep Phenotypic Analysis of Blood and Lymphoid T and NK Cells From HIV+ Controllers and ART-Suppressed Individuals. Frontiers in Immunology, 2022, 13, 803417.	2.2	12
3	The HIV-1 proviral landscape reveals that Nef contributes to HIV-1 persistence in effector memory CD4+ T cells. Journal of Clinical Investigation, 2022, 132, .	3.9	52
4	SARSâ€CoVâ€2 and Mitochondrial Proteins in Neuralâ€Derived Exosomes of COVIDâ€19. Annals of Neurology, 2022, 91, 772-781.	2.8	63
5	First-in-human immunoPET imaging of HIV-1 infection using 89Zr-labeled VRC01 broadly neutralizing antibody. Nature Communications, 2022, 13, 1219.	5.8	20
6	Role of antibodies, inflammatory markers, and echocardiographic findings in postacute cardiopulmonary symptoms after SARS-CoV-2 infection. JCI Insight, 2022, 7, .	2.3	24
7	Persistence, Magnitude, and Patterns of Postacute Symptoms and Quality of Life Following Onset of SARS-CoV-2 Infection: Cohort Description and Approaches for Measurement. Open Forum Infectious Diseases, 2022, 9, ofab640.	0.4	56
8	Characterizing the COVID-19 Illness Experience to Inform the Study of Post-acute Sequelae and Recovery. International Journal of Behavioral Medicine, 2022, 29, 610-623.	0.8	9
9	Markers of fungal translocation are elevated during post-acute sequelae of SARS-CoV-2 and induce NF-κB signaling. JCI Insight, 2022, 7, .	2.3	23
10	Markers of Immune Activation and Inflammation in Individuals With Postacute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Journal of Infectious Diseases, 2021, 224, 1839-1848.	1.9	176
11	TCF-1 regulates HIV-specific CD8+ T cell expansion capacity. JCI Insight, 2021, 6, .	2.3	43
12	Antigen-driven clonal selection shapes the persistence of HIV-1–infected CD4+ T cells in vivo. Journal of Clinical Investigation, 2021, 131, .	3.9	103
13	CpG Methylation Profiles of HIV-1 Proviral DNA in Individuals on ART. Viruses, 2021, 13, 799.	1.5	6
14	Characterization of HIV-induced remodeling reveals differences in infection susceptibility of memory CD4+ TÂcell subsets inÂvivo. Cell Reports, 2021, 35, 109038.	2.9	15
15	SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay. Science Advances, 2021, 7, .	4.7	117
16	SARS-CoV-2 Vaccination in the Context of Ongoing HIV Cure-Related Research Studies. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 87, e232-e233.	0.9	2
17	Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms. Cell Reports, 2021, 36, 109518.	2.9	142
18	HIV-1 Genomes Are Enriched in Memory CD4 <sup>+</sup> T-Cells with Short Half-Lives. MBio, 2021, 12, e0244721.	1.8	11

*Rebecca Hoh* 

#	Article	IF	CITATIONS
19	Relationship between CD4 T cell turnover, cellular differentiation and HIV persistence during ART. PLoS Pathogens, 2021, 17, e1009214.	2.1	25
20	SARS-CoV-2 booster vaccination for participants in "HIV cure―related clinical trials. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, Publish Ahead of Print, e30.	0.9	1
21	Signatures of immune selection in intact and defective proviruses distinguish HIV-1 elite controllers. Science Translational Medicine, 2021, 13, eabl4097.	5.8	52
22	High levels of genetically intact HIV in HLA-DR+ memory T cells indicates their value for reservoir studies. Aids, 2020, 34, 659-668.	1.0	32
23	Human Immunodeficiency Virus (HIV)–Infected CCR6+ Rectal CD4+ T Cells and HIV Persistence On Antiretroviral Therapy. Journal of Infectious Diseases, 2020, 221, 744-755.	1.9	39
24	Distinct viral reservoirs in individuals with spontaneous control of HIV-1. Nature, 2020, 585, 261-267.	13.7	245
25	Single-cell transcriptional landscapes reveal HIV-1–driven aberrant host gene transcription as a potential therapeutic target. Science Translational Medicine, 2020, 12, .	5.8	75
26	Antiretroviral Therapy Concentrations Differ in Gut vs. Lymph Node Tissues and Are Associated With HIV Viral Transcription by a Novel RT-ddPCR Assay. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 83, 530-537.	0.9	17
27	Different human resting memory CD4 <sup>+</sup> T cell subsets show similar low inducibility of latent HIV-1 proviruses. Science Translational Medicine, 2020, 12, .	5.8	73
28	Tissue memory CD4+ T cells expressing IL-7 receptor-alpha (CD127) preferentially support latent HIV-1 infection. PLoS Pathogens, 2020, 16, e1008450.	2.1	34
29	Impact of Antiretroviral Therapy Duration on HIV-1 Infection of T Cells within Anatomic Sites. Journal of Virology, 2020, 94, .	1.5	20
30	Longitudinal study reveals HIV-1–infected CD4+ T cell dynamics during long-term antiretroviral therapy. Journal of Clinical Investigation, 2020, 130, 3543-3559.	3.9	69
31	Filgotinib suppresses HIV-1–driven gene transcription by inhibiting HIV-1 splicing and T cell activation. Journal of Clinical Investigation, 2020, 130, 4969-4984.	3.9	26
32	Phenotypic analysis of the unstimulated in vivo HIV CD4 T cell reservoir. ELife, 2020, 9, .	2.8	63
33	A collaborative, multidisciplinary approach to HIV transmission risk mitigation during analytic treatment interruption. Journal of Virus Eradication, 2020, 6, 34-37.	0.3	17
34	Title is missing!. , 2020, 16, e1008450.		0
35	Title is missing!. , 2020, 16, e1008450.		0
36	Title is missing!. , 2020, 16, e1008450.		0

*REBECCA* Нон

#	Article	IF	CITATIONS
37	Title is missing!. , 2020, 16, e1008450.		Ο
38	Title is missing!. , 2020, 16, e1008450.		0
39	Title is missing!. , 2020, 16, e1008450.		0
40	Effector memory differentiation increases detection of replication-competent HIV-l in resting CD4+ T cells from virally suppressed individuals. PLoS Pathogens, 2019, 15, e1008074.	2.1	41
41	Memory CD4 + T-Cells Expressing HLA-DR Contribute to HIV Persistence During Prolonged Antiretroviral Therapy. Frontiers in Microbiology, 2019, 10, 2214.	1.5	38
42	Identification of NK Cell Subpopulations That Differentiate HIV-Infected Subject Cohorts with Diverse Levels of Virus Control. Journal of Virology, 2019, 93, .	1.5	41
43	Assessing intra-lab precision and inter-lab repeatability of outgrowth assays of HIV-1 latent reservoir size. PLoS Computational Biology, 2019, 15, e1006849.	1.5	22
44	PD-1 blockade potentiates HIV latency reversal ex vivo in CD4+ T cells from ART-suppressed individuals. Nature Communications, 2019, 10, 814.	5.8	149
45	Combined HIV-1 sequence and integration site analysis informs viral dynamics and allows reconstruction of replicating viral ancestors. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 25891-25899.	3.3	78
46	Some Aspects of CD8+ T-Cell Exhaustion Are Associated With Altered T-Cell Mitochondrial Features and ROS Content in HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 82, 211-219.	0.9	14
47	Reiterative Enrichment and Authentication of CRISPRi Targets (REACT) identifies the proteasome as a key contributor to HIV-1 latency. PLoS Pathogens, 2019, 15, e1007498.	2.1	46
48	Sex-Based Differences in Human Immunodeficiency Virus Type 1 Reservoir Activity and Residual Immune Activation. Journal of Infectious Diseases, 2019, 219, 1084-1094.	1.9	73
49	HIV-1 in lymph nodes is maintained by cellular proliferation during antiretroviral therapy. Journal of Clinical Investigation, 2019, 129, 4629-4642.	3.9	84
50	Estrogen receptor-1 is a key regulator of HIV-1 latency that imparts gender-specific restrictions on the latent reservoir. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E7795-E7804.	3.3	121
51	The role of CD32 during HIV-1 infection. Nature, 2018, 561, E17-E19.	13.7	43
52	Human Immunodeficiency Virus Persistence and T-Cell Activation in Blood, Rectal, and Lymph Node Tissue in Human Immunodeficiency Virus–Infected Individuals Receiving Suppressive Antiretroviral Therapy. Journal of Infectious Diseases, 2017, 215, 911-919.	1.9	95
53	Early and Delayed Antiretroviral Therapy Results in Comparable Reductions in CD8+ T Cell Exhaustion Marker Expression. AIDS Research and Human Retroviruses, 2017, 33, 658-667.	0.5	22
54	Identification of Genetically Intact HIV-1 Proviruses in Specific CD4 + T Cells from Effectively Treated Participants. Cell Reports, 2017, 21, 813-822.	2.9	304

*Rebecca* Нон

#	Article	IF	CITATIONS
55	HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study. PLoS Medicine, 2017, 14, e1002417.	3.9	186
56	A Randomized Controlled Trial of Lisinopril to Decrease Lymphoid Fibrosis in Antiretroviral-Treated, HIV-infected Individuals. Pathogens and Immunity, 2017, 2, 310.	1.4	10
57	Defective proviruses rapidly accumulate during acute HIV-1 infection. Nature Medicine, 2016, 22, 1043-1049.	15.2	605
58	Multiple Origins of Virus Persistence during Natural Control of HIV Infection. Cell, 2016, 166, 1004-1015.	13.5	156
59	Human Galectin-9 Is a Potent Mediator of HIV Transcription and Reactivation. PLoS Pathogens, 2016, 12, e1005677.	2.1	78
60	CD4+ T Cells Expressing PD-1, TIGIT and LAG-3 Contribute to HIV Persistence during ART. PLoS Pathogens, 2016, 12, e1005761.	2.1	350
61	A Novel Assay to Measure the Magnitude of the Inducible Viral Reservoir in HIV-infected Individuals. EBioMedicine, 2015, 2, 874-883.	2.7	242
62	Longitudinal Genetic Characterization Reveals That Cell Proliferation Maintains a Persistent HIV Type 1 DNA Pool During Effective HIV Therapy. Journal of Infectious Diseases, 2015, 212, 596-607.	1.9	138
63	The HIV-1 reservoir in eight patients on long-term suppressive antiretroviral therapy is stable with few genetic changes over time. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E4987-96.	3.3	260
64	Cell-Based Measures of Viral Persistence Are Associated With Immune Activation and Programmed Cell Death Protein 1 (PD-1)–Expressing CD4+ T cells. Journal of Infectious Diseases, 2013, 208, 50-56.	1.9	227
65	Comparative Analysis of Measures of Viral Reservoirs in HIV-1 Eradication Studies. PLoS Pathogens, 2013, 9, e1003174.	2.1	524
66	Impact of HIV Infection on Diastolic Function and Left Ventricular Mass. Circulation: Heart Failure, 2010, 3, 132-139.	1.6	163
67	Enfuvirtide Cerebrospinal Fluid (CSF) Pharmacokinetics and Potential use in Defining CSF HIV-1 Origin. Antiviral Therapy, 2008, 13, 369-374.	0.6	27
68	A Randomized Pilot Study Comparing Combination Therapy plus Enfuvirtide versus a Treatment Interruption followed by Combination Therapy plus Enfuvirtide. Antiviral Therapy, 2006, 11, 315-319.	0.6	9
69	Factors influencing T-cell turnover in HIV-1–seropositive patients. Journal of Clinical Investigation, 2000, 105, R1-R8.	3.9	207